Various studies have reported an inverse association between serum albumin level and incident coronary heart disease (CHD), though biologic mechanisms have not been established. The authors examined the association between serum albumin level and CHD in the Atherosclerosis Risk in Communities cohort, comprising 14,506 White and African-American middle-aged men and women. The mean albumin level in this population was 3.9 g/dl (standard deviation 0.3). During 5.2 years of follow-up, 470 incident CHD events occurred. The hazard ratio for incident CHD associated with a 1-standard deviation decrease in serum albumin level was 1.26 (95% confidence interval (Cl): 1.15,1.38) after adjustment for age, gender, and ethnicity and 1.18 (95% Cl: 1.07, 1.30) after additional adjustment for covariates related to CHD. Hazard ratios were similar across gender and ethnic groups. However, there was statistically significant effect modification by smoking status, with hazard ratios of 1.01 (95% Cl: 0.84, 1.22) among never smokers, 1.09 (95% Cl: 0.92, 1.30) among former smokers, and 1.35 (95% Cl: 1.17, 1.54) among current smokers. Further adjustment for factors related to renal disease, nutrition, platelet aggregation, inflammation, use of angiotensin-converting enzyme inhibitors, and hemostasis factors attenuated the albumin-CHD relation only slightly. In this study, serum albumin was inversely associated with incident CHD at the baseline examination in current smokers but not in never or former smokers. Albumin level may be a marker of susceptibility to the inflammatory response that results from smoking. Am J Epidemiol 2000;151:468-77. coronary disease; incidence; mortality; risk factors; serum albumin; smoking
In 1989, Phillips et al. (1) reported a marked increase in all-cause and cardiovascular disease mortality with decreasing serum albumin level among men participating in the British Regional Heart Study. The approximately 40 percent increase in risk of cardiovascular disease death associated with a 1-standard deviation decrease in serum albumin level persisted after adjustment for covariates and after deaths occurring within the first 5 years of follow-up were excluded. The investigators described this finding as possibly "serendipitous," stating that there was no prior hypothesis regarding albumin and that numerous (a total of 20) biochemical and hematologic measurements had been compared. Subsequently, other studies reported elevated relative risks for coronary heart disease (CHD) morbidity and mortality (2-A), cardiovascular disease mortality (5) , and death from all causes (4, 6, 7) in comparisons between individuals with low serum albumin levels and those with high levels, and inverse relations of serum albumin with cancer mortality (8) (9) (10) and the occurrence of stroke (11, 12) have also been found. In the single published report with negative findings, Law et al. (13) noted no relation between serum albumin and all-cause mortality among men who participated in the British United Provident Association study.
Despite these statistically strong and mostly consistent findings, published data on this relation in women and African Americans are relatively few. Moreover, a biologic mechanism for the association between albumin and cardiovascular disease and all-cause mortality has not been identified, and the finding is open to a variety of interpretations. Proposed mechanisms or confounding factors include: 1) albumin's strong correlation with inflammation and infection (2, 14, 15) ; 2) its relation to fibrinolysis and hemostasis factors (16) (17) (18) ; 3) its possible relation with platelet aggregation (19) (20) (21) ; 4) its role as an antioxidant (22, 23) ; 5) its possible role as a marker of increased vascular permeability due to underlying disease (2, 6, 16, (24) (25) (26) (27) ; and 6) its relation to nutritional status (1, 12) .
This study was designed to determine prospectively whether there is an inverse relation between serum albumin level and incident CHD, and to examine the potential mediators of the association.
MATERIALS AND METHODS

Study population
The Atherosclerosis Risk in Communities (ARIC) study population, described in detail elsewhere (28) , was selected as a probability sample of 15,792 men and women aged 45-64 years at four US study centers, three of which enumerated and enrolled an ethnically representative population (selected suburbs of Minneapolis, Minnesota and Washington County, Maryland, comprising almost entirely Whites, and Forsyth County, North Carolina, comprising approximately 15 percent African Americans). The fourth center sampled exclusively African-American residents of Jackson, Mississippi. Forty-six percent of eligible persons in Jackson and 65-67 percent of those eligible in the other communities underwent a home interview and clinic examination in 1987-1989. Participants were reexamined in 1990-1992 and again in 1993-1995. Annual telephone calls were made to assess hospitalizations and mortality between clinic visits. Ascertainment has been complete for 97 percent of participants. We excluded a total of 1,286 participants (8.1 percent) whose CHD status could not be determined (n = 348) or who had baseline prevalent CHD (n -772), were of an ethnicity other than White or African-American {n = 48), or were missing a value for serum albumin (n = 150); this left 14,506 participants in the study sample.
Baseline measurements
Blood from the antecubital vein of each seated participant was drawn by a technician into vacuum tubes containing ethylenediaminetetraacetic acid (lipids), sodium citrate (fibrinogen), or separator gel (biochemical assays), and tubes were centrifuged at 3,000g for 10 minutes at 4°C. Aliquots were frozen shortly after separation, and assays were performed within a few weeks. The University of Minnesota Clinical Chemistry Laboratory measured albumin concentrations with a Coulter DACOS instrument (Coulter Diagnostics, Hialeah, Florida) using Coulter's bromcresol green colorimetric assay (29) . The reliability coefficient of albumin measurements, based on repeated testing of 40 healthy participants who were similar to ARIC participants on days 1,14, and 28, was 0.69, and the within-person variability was 2.8 percent (30) . Other biochemical assays and measurement of lipids and lipoproteins and hemostasis factors were carried out using standardized methods monitored by established quality control procedures (31) .
At the baseline examination, each participant's weight and height were measured while he or she stood in a scrub suit, without shoes. Body mass index (weight (kg)/height (m) 2 ) was then computed. Waist (umbilical level) and hip (maximum of buttocks) circumferences were used to compute waist:hip ratio. Three blood pressure measurements were taken using a random-zero sphygmomanometer, and the mean of the last two values was used for analysis. Prevalent hypertension was defined as systolic pressure >140 mmHg, diastolic pressure >90 mmHg, or the use of antihypertensive medication(s) within the 2 weeks prior to the baseline examination. Because an oral glucose tolerance test was not performed, prevalent diabetes mellitus was defined as a fasting glucose level 140 mg/dl, a nonfasting glucose level >200 mg/dl, a self-reported history of diabetes, or the use of hypoglycemic agents. Pack-years of cigarette smoking for former and current smokers was defined as the average number of cigarettes smoked per day multiplied by the number of years smoked. Prevalent CHD at baseline was defined as a reported history of physiciandiagnosed heart attack, evidence of a prior myocardial infarction by electrocardiogram (presence of a major Q-wave abnormality or a minor Q-wave abnormality with T-wave or S-T segment abnormality), or a selfreport of a prior coronary reperfusion procedure.
Ascertainment of incident events
Incident CHD events were ascertained by several methods. The methods used included annual telephone contacts with participants (or relatives, for the deceased) to identify hospitalizations and deaths occurring during the prior year; surveys of discharge lists from local hospitals and death certificate tapes from state vital statistics offices; and review of 12-lead electrocardiograms performed every 3 years at ARIC clinic visits to detect unrecognized myocardial infarction. For hospitalized ARIC participants, trained abstractors recorded presenting signs and symptoms, including chest pain, elevated cardiac enzyme levels, and results of up to three electrocardiograms taken during the hospitalization and coded using the Minnesota diagnostic code. Out-of-hospital deaths were investigated by means of death certificates, interviews with next of kin, and questionnaires completed by the participants' physicians. Coroner reports and autopsy reports were used when available. All potential clinical CHD events were reviewed and adjudicated by the ARIC Morbidity and Mortality Classification Committee using previously published criteria (28) . Unrecognized myocardial infarction was defined by the appearance between the first and subsequent ARIC examinations of a major Q-wave abnormality with ischemic S-T segment/Twave changes or the ascertainment of a myocardial infarction by computerized NOVACODE (32) criteria, confirmed by side-by-side visual electrocardiogram comparison. CHD incidence for this analysis was defined as a validated hospitalized myocardial infarction, CHD death, unrecognized myocardial infarction at the 3-or 6-year follow-up examination, or hospitalized coronary artery bypass surgery or angioplasty.
Statistical analysis
Mean levels or proportions of potential CHD risk factors were computed by quartiles of serum albumin level, which were derived from the entire sample distribution. Age-, ethnicity-, and gender-adjusted correlations of serum albumin with CHD risk factors were assessed using Pearson correlation coefficients for continuous factors and comparing mean differences for categories of discrete factors. Analysis of covariance (33) was used to compare the adjusted mean levels of serum albumin by incident CHD status. Poisson regression (34) was used to estimate adjusted CHD incidence rates by quartile of serum albumin. Cox proportional hazards models were used to estimate the hazard of incident CHD, adjusting for other risk factors (35) . Log (-log(survival)) curves were plotted by quartile of serum albumin and were found to be parallel, thereby confirming the assumption of proportionality of hazards. A quadratic term included in the models was statistically nonsignificant, indicating a log-linear association between serum albumin level and hazard of incident CHD. To explore the possibility of differing associations across communities, we performed an analysis among Whites at the three predominantly White centers, including a proportional hazards analysis testing for site and site-albumin interactions. Using a criterion of p < 0.20 for statistical significance, none of the interaction terms indicated a different albumin-CHD association across the communities. In a similar fashion, we examined site and site-albumin interactions among African Americans at the two centers with a sizable number of African-American participants and found no statistically or qualitatively significant indication of an interaction. Because this was an exploratory analysis, all factors under inspection (23 in total) were considered possible effect modifiers and were tested in the proportional hazards models. No adjustment was made for multiple testing, though all positive findings have been reported in this paper. All statistical tests were two-tailed, and analyses were performed using SAS, version 6.10 (36).
RESULTS
Among the 14,506 participants without prevalent CHD at baseline, 470 (3.2 percent) experienced an incident CHD event during an average follow-up period of 5.2 years. Serum albumin values were approximately normally distributed, with a range of 2.0-5.1 g/dl, a mean and median of 3.9 g/dl, a standard deviation of 0.3 g/dl, and an interquartile range of 0.3 g/dl. The mean albumin level was slightly lower in women (3.83 g/dl) than in men (3.92 g/dl) and slightly lower in African Americans (3.81 g/dl) than in Whites (3.89 g/dl). The mean albumin level was 3.87 g/dl for never smokers, 3.90 g/dl for former smokers, and 3.85 g/dl for current smokers. The mean albumin level was markedly lower in participants with diabetes than in those without the condition (difference = 0.10 g/dl). Mean serum albumin, adjusted for age, ethnicity, and gender, was statistically significantly lower in participants who experienced a CHD event during follow-up (3.81 g/dl) than in event-free participants (3.86 g/dl) (p< 0.0001).
Baseline characteristics of participants by quartiles of serum albumin are presented in table 1. Consistent with differences in mean albumin levels by gender and ethnicity, higher percentages of women and African Americans were in the low quartiles of serum albumin. The percentage of participants who had never smoked cigarettes did not vary across quartiles of albumin, but a higher proportion of current smokers and a lower proportion of former smokers were in the low quartiles of albumin as opposed to the high quartiles. The percentage of participants with diabetes was twice as high among participants in the lowest quartile of albumin as among those in the fourth quartile. The percentage of participants who used angiotensin-converting enzyme inhibitors, which are known to lower renal albumin loss, was slightly higher in the first quartile than in the second through fourth quartiles. Consistent with the mean values shown in table 1, when we adjusted for age, ethnic group, and gender, serum albumin was found to be directly correlated with low density lipoprotein cholesterol (partial correlation coefficient: r = 0.15), protein C (r = 0.13), hematocrit (r = 0.16), and total protein (r = 0.49) and inversely correlated with body mass index (r = -0.16), fibrinogen (r = -0.19), factor Vm (r = -0.16), von Willebrand factor (r = -0.14), and white blood cell count (r = -0.12).
No strong correlations or large differences in mean values were seen for the remaining variables under inspection.
In comparisons of participants with low serum albumin levels and those with high levels, there was a clear, monotonic increase in age-and ethnicityadjusted CHD incidence rates for both men and women ( figure 1) (table 3) . Examination of the albuminincident CHD association by quartile of serum albumin level showed that the hazard ratios for incident CHD, after adjustment for the above covariates, among never and former smokers were 1.13, 1.10, 1.08, and 1.00 (referent) from the lowest quartile of serum albumin to the highest (figure 2). In comparison, adjusted hazard ratios among current smokers were 1.95, 1.68, 1.25, and 1.00 (referent) from the lowest quartile of serum albumin to the highest.
In an attempt to address possible biologic pathways, we examined the effects of covariates related to hemostasis, inflammation, platelet aggregation, renal disease, nutrition, and vascular permeability on the serum albumin-CHD association. Among smokers, adjustment for pack-years of cigarette smoking or number of cigarettes smoked per day did not alter the point estimate of the hazard ratio in any of the models. Adjustment for diabetes in addition to other covariates decreased the hazard ratio from 1.43 to 1.40. Exclusion of participants with diabetes or with a serum creatinine level greater than 2 mg/dl had little effect on the hazard ratio or the level of statistical significance. Further adjustment for fibrinogen decreased the hazard ratio from 1.40 to 1.35. The hazard ratio from the proportional hazards model containing the major CHD covariates changed only trivially when the following variables were added individually: factor VII, factor VIII, protein C, antithrombin IE, von Willebrand factor, hematocrit, total protein, white blood cell count, platelet count, serum creatinine, and use of angiotensinconverting enzyme inhibitors. Effect modification was suggestive for two hemostasis factors. CHD risk was greater in participants with low or moderate levels of antithrombin HI than in those with high levels (in a test for interaction using a 1-standard deviation decrease in serum albumin level, p -0.0004); hazard ratios for CHD risk across tertiles of serum albumin were: fertile 1, 1.46 (95 percent CI: 1.08, 1.96); tertile 2, 1.60 (95 percent CI: 1.28, 2.00); and tertile 3, 1.07 (95 percent CI: 0.85, 1.34). CHD risk was slightly greater in partic- 
DISCUSSION
In this ARIC cohort, a statistically significant inverse association was found between serum albumin level and incident CHD, both overall and among individuals who were current smokers at baseline. The overall inverse association is consistent with the findings of earlier studies. In a population-based, middleaged cohort of British men, Phillips et al. (1) observed a relative risk of approximately 1.4 for cardiovascular disease mortality with a 1-standard deviation decrease (0.26 g/dl) in serum albumin. In a clinical trial of mostly White, middle-aged men at high risk for CHD, Kuller et al. (2) reported that the risk of CHD morbidity and mortality was two times higher in men in the lowest quintile of serum albumin level compared with the highest. Among participants in the NHANES I Epidemiologic Follow-up Study, Gillum and Makuc (5) detected statistically significant age-, gender-, and race-specific relative risks between 1.35 and 1.89 for cardiovascular disease mortality when comparing the lowest albumin tertile with the highest. In a study population of elderly men and women, of whom approxi- 2. Adjusted hazard ratios for incident coronary heart disease by smoking status and quartile of serum albumin level (<3.70, 3.70-3.89, 3.90-4.00, and >4.00 g/dl), using the highest quartile of serum albumin as the reference group, Atherosclerosis Risk in Communities Study, 1987-1993. Data were adjusted for age, gender, ethnicity, diabetes, hypertension, low density lipoprotein cholesterol, high density lipoprotein cholesterol, trigtycerides, body mass index, waist:hip ratio, pack-years of smoking, and fibrinogen. Bars, 95% confidence interval (Cl).
mately half were hyperlipidemic, Klonoff-Cohen et al. (6) observed a relative risk of 1.24 for death from all causes associated with a 1-standard deviation decrease in serum albumin. In the Paris Health Study (37) , there was a statistically significant inverse association of serum albumin with total mortality in male participants but not in female participants. In a case-control analysis carried out within a prospective study of Solomon Islanders, men who died had a lower mean serum albumin level than those who survived, but no difference in mean albumin was observed for female cases or controls (10) . Conversely, in an elderly cohort of 4,116 men and women followed for 4 years, the relative risk of CHD mortality was higher in women with low serum albumin concentrations than in women with high concentrations, and there was a graded increase in CHD incidence with decreasing albumin level in women, though the relation was not found in men (3). In another elderly cohort comprising all men, a moderately low serum albumin level was predictive of CHD mortality and all-cause mortality, independent of traditional risk factors; the finding was not explained by baseline health status (4) .
When the results of eight prospective, populationbased studies were combined into a composite body of evidence using data synthesis (38) , individuals with serum albumin levels in the bottom third compared with the top third had a combined CHD risk ratio of 1.5 (95% confidence interval, 1.3-1.7). In another systematic overview involving 10 studies of large size and adequate design (39), mortality was predicted by serum albumin concentration across a broad range of serum values in populations with and without disease. In the single published report with negative findings (13), there was no relation between serum albumin level and all-cause mortality among men who participated in the British United Provident Association study; however, there may have been low statistical power to detect a difference in this cohort comprising healthy employed men who sought routine health examinations, since men with acute or chronic diseases would have gone instead to a specialist clinic (according to the authors). In our cohort, we observed statistically significant inverse associations of serum albumin with CHD incidence and mortality in both men and women and in both Whites and African Americans. Although all-cause mortality was not the focus of this paper, we also observed a statistically significant relation of serum albumin with total mortality.
In addition to determining whether a serum albumin-incident CHD association existed in the ARIC cohort, our aim was to determine whether serum albumin serves as a marker for or an intervening element of another condition or risk factor that itself leads to cardiovascular disease, although such interpretations are constrained by the use of cross-sectional observation of the associations between albumin and other measurements. A noteworthy finding of this study is that the serum albumin-incident CHD relation was confined to current smokers (with an absence of this relation among never and former smokers). Kuller et al. (2) also observed a lack of association between albumin level and CHD death among nonsmokers, though a formal test for smoking interaction yielded no statistical significance.
It is unlikely that serum albumin level is merely a marker for smoking intensity. The correlation of albumin with pack-years of smoking was weak, and there was little effect on the albumin-CHD relation after adjustment for pack-years of cigarette smoking and number of cigarettes smoked per day. Residual confounding cannot be ruled out, but it is unlikely.
Serum albumin is a negative acute-phase reactant that is synthesized by the liver (40) . In inflammatory states, the activity of macrophages and other immune system cells is enhanced, leading to production of cytokines, which switch protein synthesis in the liver from serum albumin to other acute-phase proteins. Chronic inflammation, as well as infection, has been linked to CHD (41, 42) and to atherosclerosis (43, 44) . Cigarette smoking is related to pulmonary infections and is itself a chronic inflammatory stimulus of considerable intensity (45) . It is conceivable that reduced albumin may be indicative of a generalized inflammatory response-in this instance, inflammation caused by smoking-and that smokers with the lowest levels of albumin may be those whose inflammatory response is the greatest. Instead of a dose-response relationship indicative of smoking intensity, low levels of albumin may be characteristic of individuals whose response to the insults of smoking indicates increased susceptibility, at least at the level of hepatic response. This hypothesis may be supported by the inverse associations between albumin and other elements involved in acute-phase response mechanisms-some of them inflammatory-such as white blood cell count, factor VH[, and fibrinogen.
Low serum albumin concentration is also related to attenuated fibrinolysis (17, 18) . Unfortunately, we do not have measures of fibrinolysis for the full ARIC cohort. In our study population, however, low serum albumin level was associated with several hemostatic factors: higher levels of fibrinogen, factor VIII, and von Willebrand factor and a lower level of protein C. Adjustment for fibrinogen slightly reduced the association between albumin and incident CHD but did not eliminate the association. Adjustment for other hemostasis factors had very little influence on the albumin-CHD relation.
Because several studies have established a link between microalbuminuria and vascular disease mortality (46, 47), we also examined whether serum albumin was a marker for renal disease, as is the case for renovascular damage due to diabetes mellitus (48, 49) . We found that diabetes as a covariate attenuated the albumin-CHD relation only slightly, and that the association was essentially unchanged when the analysis was restricted to participants with no diabetes or to those with serum creatinine levels less than 2 mg/dl. However, serum creatinine level and the presence of diabetes were the only surrogates of renal function available to us, and because serum creatinine is a weak indicator of renal dysfunction, a role of renal disease in explaining our findings cannot be totally discounted.
Other investigators (2, (25) (26) (27) have proposed that the relation between hypoalbuminuria and mortality may reflect a generalized increase in vascular permeability found in malignancy, infection, and ischemia. In two recent studies by Jensen et al., urinary albumin excretion and transvascular albumin leakage were statistically significantly higher in patients with severe clinical atherosclerosis than in healthy controls (26) , and microalbuminuria was an independent marker of systemic transvascular albumin permeability in a small study of clinically healthy participants (27) . Fleck et al. (25) have demonstrated that a fall in serum albumin level after surgery is due to increased vascular permeability. Renal vascular permeability is increased by ischemia, and increased urinary albumin excretion is seen immediately after exercise-induced muscle ischemia (24) . Elevated blood pressure correlates with urinary albumin excretion (50) and vascular permeability (24) . In our study, hypertension at baseline was not an effect modifier, nor did it substantially confound the relation of albumin with CHD incidence, which suggests that vascular permeability resulting from hypertension may not be a causal pathway.
Using hematocrit and total serum protein as proxy measures of nutritional status, we found that each factor attenuated the albumin-incident CHD relation slightly, but neither eliminated the association, nor was either factor an effect modifier of the albumin-CHD relation. It is unlikely, however, that hypoalbuminuria results from insufficient dietary intake of protein in this population. Protein intake must drop to very low levels to cause hypoalbuminuria in healthy men (8) ; serum levels are generally insensitive to short term changes in protein intake (2); and albumin is neither specific nor sensitive as an index of nutritional status, because of the large number of factors that alter its metabolism (51) .
Serum albumin interacts with free fatty acids, inhibiting their promoting effect on platelet aggregation in vitro (20) . De Lorgeril et al. (19) found a statistically significant inverse relation between serum albumin and adenosine diphosphate-induced platelet aggregation ex vivo, and they proposed that albumin may be related to incident CHD through this pathophysiologic mechanism. Since no measurements of platelet aggregation or adhesion were conducted in this cohort, we were limited to the use of platelet count as a crude index by which to explore this possible explanation, and we found that platelet count did not attenuate the serum albumin-incident CHD association when added as a covariable in the proportional hazards models.
Another possible explanation for the serum albumin-CHD relation that we could not address directly in this analysis relates to the role of serum albumin as an antioxidant. Albumin has specific binding sites for copper ions, which are able to accelerate free radical reactions, and albumin may function as an antioxidant by scavenging peroxyl radicals (22) . Furthermore, conjugated linoleic acids are potent antioxidants (22) , and the production of conjugated linoleic acids from linoleic acids requires protein (52), the most abundant of which is serum albumin.
A potential limitation of this study warrants consideration. Serum albumin was assessed at only one point in time, and by means of a single measurement. Any measurement error was probably nondifferential between participants with and without incident CHD, and the impact would probably bias results toward an apparent lack of a statistically significant association. Moreover, the consistency of our results with those of several other studies and the graded and strong associations identified suggest that the findings of an overall association and a smoking interaction are nonspurious.
In summary, in approximately 5 years of follow-up of a middle-aged, population-based cohort of 14,506 White and African-American men and women, the risk of incident CHD was higher in current smokers with low serum albumin levels at baseline than in those with higher albumin levels. The association persisted after adjustment for several CHD risk factors, including factors proposed by other investigators as possible intervening factors in an association with serum albumin, such as diabetes and smoking intensity. The serum albumin-CHD relation was absent among never and former smokers. Our findings are consistent with the interpretation that serum albumin is a marker of susceptibility to the inflammatory response that results from cigarette smoking.
